Relief Therapeutics prepares for Nasdaq listing following transition into commercial-stage company
New York
|
May 09, 2023 07:36 AM Eastern Daylight Time
Relief Therapeutics CEO Jack Weinstein tells Proactive's Stephen Gunnion that a reverse 1-for-400 stock split has taken effect at the company as it targets a listing on the Nasdaq in a move that will raise its profile and attract more institutional investors.
Weinstein also takes Proactive through the company's commercial and development drug pipeline as it makes progress with its transformation into a commercial-stage biopharmaceuticals company, identifying, developing and commercializing novel, patent-protected products in selected specialty, rare and ultra-rare disease areas on a global basis.
Contact Details
Proactive Investors
+1 347-449-0879
